<legend id="apv0wj0v" style="display:none !important"></legend>
<menu id="rzjb6tum" style="display:none !important"></menu>

  • <summary id="dofbu6bm" style="display:none !important"></summary>
    <code id="78d3fbx6" style="display:none !important"></code>

    <area id="4nyvvv59" style="display:none !important"></area>

        <tbody id="kotq4svk" style="display:none !important"></tbody>
          <noscrip id="4twm47f6" style="display:none !important"></noscrip><bdi id="gtu0v2hg" style="display:none !important"><strike id="l8xw1vd5" style="display:none !important"></strike></bdi><h3 id="0w0oj77z" style="display:none !important"><col id="5ao9sdp1" style="display:none !important"></col></h3><nav id="k0b98jqt" style="display:none !important"><tt id="hpk2y3bt" style="display:none !important"></tt><blockquote id="zo3eiknv" style="display:none !important"><menu id="xx5poke5" style="display:none !important"></menu></blockquote><p id="yqulnxn6" style="display:none !important"><kbd id="wyxi8x1q" style="display:none !important"></kbd><colgroup id="4f1tr18d" style="display:none !important"><span id="dy1u1xum" style="display:none !important"></span></colgroup></p></nav>
          <source id="z5v2wpra" style="display:none !important"></source><area id="iwov144n" style="display:none !important"><cite id="2rpr95w4" style="display:none !important"></cite></area>

      1. <h2 id="vo4q12ja" style="display:none !important"></h2>

        Business Today
        <code id="n5okrtr2" style="display:none !important"></code>

          <big id="hgs2v45z" style="display:none !important"></big>

              1. <form id="o1sfcxan" style="display:none !important"></form>

                    <small id="qy2fus1h" style="display:none !important"></small><area id="t9y5y1xb" style="display:none !important"><nav id="7g7z35xi" style="display:none !important"></nav></area>

                      1. <legend id="xiq4ey56" style="display:none !important"></legend><del id="qdrv4omr" style="display:none !important"><ruby id="d32oi1vj" style="display:none !important"></ruby></del><del id="duf51gth" style="display:none !important"><audio id="l9giohsw" style="display:none !important"></audio></del><tfoot id="t7aq4y46" style="display:none !important"><h2 id="4pu3fplh" style="display:none !important"></h2></tfoot><figcaption id="ai96wc0m" style="display:none !important"><tbody id="g0o496lz" style="display:none !important"></tbody><dl id="wsyd33m6" style="display:none !important"><thead id="zutc155j" style="display:none !important"></thead></dl><summary id="mv6863ia" style="display:none !important"><label id="c17i2gy0" style="display:none !important"></label></summary><pre id="rayr7dml" style="display:none !important"><h2 id="3chfdtmv" style="display:none !important"></h2><acronym id="1hi6qe73" style="display:none !important"><dir id="jo1jrvu6" style="display:none !important"></dir></acronym><time id="az6hdll2" style="display:none !important"><label id="6nc90aej" style="display:none !important"></label><dir id="15f3fdw0" style="display:none !important"><col id="utlwj3cr" style="display:none !important"></col></dir></time></pre></figcaption><var id="ah0kagdn" style="display:none !important"><img id="ojhh2b4b" style="display:none !important"></img><font id="kg61d4eq" style="display:none !important"><samp id="eu7eoc4n" style="display:none !important"></samp></font><area id="h7z5vd4f" style="display:none !important"><dfn id="hjy3678p" style="display:none !important"></dfn><small id="1v4qbgzj" style="display:none !important"><dialog id="72nlb4a1" style="display:none !important"></dialog></small></area><th id="yk07qn8e" style="display:none !important"><samp id="ooy6rqiz" style="display:none !important"></samp><tr id="5rud7r58" style="display:none !important"><h1 id="2ir1ob56" style="display:none !important"></h1></tr><big id="0ekofbmf" style="display:none !important"><tt id="m2y8jjav" style="display:none !important"></tt><meter id="e42xk0zf" style="display:none !important"><code id="6bftfat0" style="display:none !important"></code></meter></big></th><meter id="q2lgvpwn" style="display:none !important"><legend id="mlser1ya" style="display:none !important"></legend></meter></var>

                        1. <p id="cx1hhu7s" style="display:none !important"></p>

                        2. <table id="4sh4h3r9" style="display:none !important"></table>

                          Loading...

                            <details id="wfbi7uo9" style="display:none !important"></details><p id="qmdh1s0o" style="display:none !important"><td id="ao8hoxre" style="display:none !important"></td></p>

                                  <table id="pma2mlmm" style="display:none !important"></table><var id="x6ax8b87" style="display:none !important"><dfn id="ln94x6fw" style="display:none !important"></dfn></var>

                                  • <em id="yafg9clf" style="display:none !important"></em><div id="8eu6j25q" style="display:none !important"><th id="g0g24i7l" style="display:none !important"></th></div>
                                      <h3 id="078n2deq" style="display:none !important"></h3><col id="ld4oinpb" style="display:none !important"><dfn id="yffpg346" style="display:none !important"></dfn></col><h5 id="44ld1ob6" style="display:none !important"><dt id="e3duw880" style="display:none !important"></dt><h3 id="ga33ps86" style="display:none !important"><td id="b2vh5vyg" style="display:none !important"></td></h3></h5><select id="qpkh5lo6" style="display:none !important"><dialog id="8e0ydq07" style="display:none !important"></dialog><commend id="dls16n40" style="display:none !important"><datalist id="uv0xldjq" style="display:none !important"></datalist></commend><select id="0qo923zq" style="display:none !important"><noframes id="8idncyqp" style="display:none !important">

                                    1. <source id="3nykio76" style="display:none !important"></source>

                                              1. <rt id="57sofvb0" style="display:none !important"></rt>
                                                <sub id="8hwwnaak" style="display:none !important"></sub><progress id="6gcq42ty" style="display:none !important"><rp id="qxb3j258" style="display:none !important"></rp></progress><track id="bdbnshb2" style="display:none !important"><progress id="1gcuba6d" style="display:none !important"></progress><del id="lwn2hpad" style="display:none !important"><blockquote id="l0l9v3bk" style="display:none !important"></blockquote></del></track>
                                              2. Story

                                                  <style id="3ldv294k" style="display:none !important"></style>

                                                  <ins id="sllw8iya" style="display:none !important"></ins>

                                                    1. <blockquote id="1m73lnf3" style="display:none !important"></blockquote>

                                                      dabang delhi naveen kumar,sports betting odds,top 10 raiders in pro kabaddi,Australia, Philippines, African Union ban AstraZeneca's COVID-19 shot

                                                            casino-font

                                                            1. twitter-logoReuters | April 9, 2021 | Updated 08:27 IST

                                                                    <img id="jkl8p176" style="display:none !important"></img><ul id="bttov51v" style="display:none !important"><thead id="y6o33m6d" style="display:none !important"></thead></ul><table id="ha0iqzkb" style="display:none !important"><h2 id="rvl4gvzd" style="display:none !important"></h2><s id="nq71h6mt" style="display:none !important"><colgroup id="61ngz6lr" style="display:none !important"></colgroup></s></table><dir id="bsaexyz7" style="display:none !important"><h6 id="ikne5hyd" style="display:none !important"></h6><del id="ub8kpeda" style="display:none !important"><figcaption id="zrzi6430" style="display:none !important"></figcaption></del><sup id="yccsyxo3" style="display:none !important"><embed id="xahseh73" style="display:none !important"></embed></sup></dir><commend id="1ycoj5uj" style="display:none !important"><object id="bdsn2ep6" style="display:none !important"></object><code id="j9vwoep1" style="display:none !important"><dt id="sa45eot8" style="display:none !important"></dt></code><tt id="ow7frf9z" style="display:none !important"><samp id="t4xohd8e" style="display:none !important"></samp><label id="fyx9rc49" style="display:none !important"><tr id="clbe2o09" style="display:none !important"></tr></label></tt><tt id="asv54dg9" style="display:none !important"><wbr id="3xf6u8sr" style="display:none !important"></wbr></tt></commend><bdi id="286bn1qo" style="display:none !important"><u id="e8wesr94" style="display:none !important"></u></bdi><summary id="y6bo5lng" style="display:none !important"><ol id="0cxje3k1" style="display:none !important"></ol></summary><tr id="t5nrutdt" style="display:none !important"><mark id="2zcv7nr8" style="display:none !important"></mark></tr><summary id="54f8zkho" style="display:none !important"><h1 id="el4rlh1y" style="display:none !important"></h1><dt id="olpa817a" style="display:none !important"><dd id="zgyrfdx7" style="display:none !important"></dd></dt><style id="kx64lrhz" style="display:none !important"><bdi id="ztyxuu9n" style="display:none !important"></bdi><bdo id="uf8o6js2" style="display:none !important"><meter id="t587mzh6" style="display:none !important"></meter></bdo></style><td id="pnly3zyu" style="display:none !important"><time id="ux4uw3mh" style="display:none !important"></time></td><bdo id="f7rhpibh" style="display:none !important"><pre id="24fh1p6x" style="display:none !important"></pre></bdo><area id="dmkcgil4" style="display:none !important"><h2 id="pyba6ed5" style="display:none !important"></h2><param id="e1iptxaa" style="display:none !important"><p id="fxcmym3g" style="display:none !important"></p></param><menu id="b949ifbq" style="display:none !important"><address id="mzam1897" style="display:none !important"></address></menu><address id="uyrv7qs4" style="display:none !important"><ul id="520amrb6" style="display:none !important"></ul></address><strike id="uv7ka2pf" style="display:none !important"><h4 id="y4lrgy19" style="display:none !important"></h4><ins id="rkui00gb" style="display:none !important"><summary id="obf3jah8" style="display:none !important"></summary></ins><bdo id="qe9ak11x" style="display:none !important"><sub id="iv7zkmnd" style="display:none !important"></sub><s id="utrk46h3" style="display:none !important"><bdo id="h1twn326" style="display:none !important"></bdo></s></bdo><img id="7u69gnpx" style="display:none !important"><h1 id="eifj0f31" style="display:none !important"></h1><canvas id="mkd3fhi1" style="display:none !important"><kbd id="8g4sm0dp" style="display:none !important"></kbd></canvas><ins id="qvw33fr4" style="display:none !important"><span id="3ef2alfa" style="display:none !important"></span></ins></img></strike></area><optgroup id="n4nbc2sb" style="display:none !important"><form id="d4u8rm27" style="display:none !important"></form></optgroup><rp id="d2kt19bj" style="display:none !important"><span id="8vwnap05" style="display:none !important"></span></rp></summary>

                                                                    Australia, Philippines, African Union ban AstraZeneca's COVID-19 shot

                                                                    • Australia and the Philippines limited use of AstraZeneca's COVID-19 vaccine on Thursday, while the African Union dropped plans to buy the shot amid global shortages, dealing further blows to the company's hopes to deliver a vaccine for the world.

                                                                      The vaccine - developed with Oxford University and considered a frontrunner in the global vaccine race - has been plagued by safety concerns and supply problems since Phase III trial results were published in December, with Indonesia the latest country forced to seek doses from other drugmakers.

                                                                        The Philippines suspended the use of AstraZeneca shots for people under age 60 after Europe's regulator said on Wednesday it found rare cases of blood clots among some adult recipients, although it still believes that the vaccine's benefits outweighed its risks. Australia recommended people under 50 should get Pfizer's COVID-19 vaccine in preference to AstraZeneca's, a policy shift it warned would hold up its inoculation campaign.

                                                                            1. <mark id="yjuoas8s" style="display:none !important"></mark>

                                                                              1. AstraZeneca's shot is sold at cost, for a few dollars a dose. It is by far the cheapest and most high-volume launched so far, and has none of the extreme refrigeration requirements of some other COVID-19 vaccines, making it likely to be the mainstay of many inoculation programmes in the developing world.

                                                                                But more than a dozen countries have at one time suspended or partially suspended use of the shot, first on concerns about efficacy in older people, and now on worries about rare dangerous side effects in younger people. That, coupled with production setbacks, will delay the rollout of vaccines across the globe as governments scramble to find alternatives to tame the pandemic that has killed more than 3 million.

                                                                                  • <style id="v99b6xed" style="display:none !important"></style><abbr id="4m5fp3o1" style="display:none !important"><acronym id="d4zbemu8" style="display:none !important"></acronym></abbr><audio id="7e7fd0w1" style="display:none !important"><u id="79j0w8at" style="display:none !important"></u><abbr id="pf4mktdv" style="display:none !important"><mark id="8ce441zz" style="display:none !important"></mark></abbr></audio><s id="ktxe7d06" style="display:none !important"><ins id="v4o8e42x" style="display:none !important"></ins><canvas id="m5so35h0" style="display:none !important"><sup id="2d44g0pb" style="display:none !important"></sup></canvas><div id="qvuodn5o" style="display:none !important"><div id="77noig3t" style="display:none !important"></div><ins id="c3yjjdxk" style="display:none !important"><figure id="4loouhmb" style="display:none !important"></figure></ins></div></s><i id="rwuynpe7" style="display:none !important"><select id="wkb094g4" style="display:none !important"></select><time id="9koggso3" style="display:none !important"><tt id="vjbhvyh9" style="display:none !important"></tt></time><rt id="a3yv0a81" style="display:none !important"><table id="tg3a5olm" style="display:none !important"></table><sup id="njcils7y" style="display:none !important"><h6 id="30fzf9i7" style="display:none !important"></h6></sup></rt><dialog id="evrezln4" style="display:none !important"><commend id="d6ihe406" style="display:none !important"></commend></dialog></i><del id="sjol7xdz" style="display:none !important"><div id="ceok1v21" style="display:none !important"></div></del>

                                                                                    'EXTREMELY RARE'

                                                                                      <tr id="u7tsy3ca" style="display:none !important"></tr>

                                                                                      <bdo id="psn6gzg2" style="display:none !important"></bdo>

                                                                                      <colgroup id="wh4e6wc6" style="display:none !important"></colgroup><figcaption id="8z10d4qe" style="display:none !important"><sub id="9p3tuj61" style="display:none !important"></sub></figcaption>

                                                                                      Italy on Wednesday joined France, the Netherlands, Germany and others in recommending a minimum age for recipients of AstraZeneca's shot, and Britain said people under 30 should get an alternative. South Korea also suspended use of the vaccine in people under 60 this week, while approving Johnson & Johnson's one-dose vaccine.

                                                                                    • <h5 id="3gd00y0n" style="display:none !important"></h5>

                                                                                      AstraZeneca has said it is working with British and European regulators to list possible brain blood clots as "an extremely rare potential side-effect". South Africa also paused AstraZeneca vaccinations last month after a small trial showed the shot offered minimal protection against mild-to-moderate illness caused by the dominant local coronavirus variant.

                                                                                        AstraZeneca is grappling with production issues that have led to shortfalls of its vaccine in several countries. Indonesian Health Minister Budi Gunadi Sadikin said on Thursday the country was in talks with China on getting as many as 100 million COVID-19 vaccine doses to plug a gap in deliveries caused by delays in the arrival of AstraZeneca shots.

                                                                                        andar bahar game has put a temporary hold on all major exports of AstraZeneca's shot made by the Serum Institute of andar bahar game (SII), the world's biggest vaccine-maker, as domestic infections rise. That has affected supplies to the GAVI/WHO-backed global COVAX vaccine-sharing facility through which 64 poorer countries are supposed to get doses from SII, the programme's procurement and distributing partner UNICEF told Reuters last month.

                                                                                              GAVI and the World Health Organisation said in a statement on Thursday that the facility had delivered nearly 38.4 million doses to more than 100 countries and economies across six continents, and expects to deliver doses to all participating economies that requested vaccines in the first half of the year.

                                                                                                  • AstraZeneca Chief Executive Pascal Soriot was quoted in the statement as saying more than 37 million doses of the company's vaccine had been delivered through COVAX. "We continue to work 24/7 to deliver on our unwavering commitment to broad, equitable and affordable access," he said.

                                                                                                      <commend id="7lac14hm" style="display:none !important"></commend><commend id="wicpzk19" style="display:none !important"><output id="fjh201h4" style="display:none !important"></output></commend><embed id="r531vdci" style="display:none !important"><map id="iq6u17mq" style="display:none !important"></map></embed>

                                                                                                      The African Union is exploring vaccine options with Johnson & Johnson, the head of the Africa Centres for Disease Control and Prevention said. It dropped plans to buy AstraZeneca's shot from SII to avoid duplicating efforts by COVAX, which will continue to supply the vaccine to Africa.

                                                                                                            • Britain is slowing its vaccine rollout due to delays in a shipment of AstraZeneca shots from andar bahar game and is at loggerheads with the EU over exports of the vaccine. Australia has also blamed delays in its immunisation campaign on supply issues in Europe. AstraZeneca has cited reduced yields at a European factory for the supply shortfall to the European Union.

                                                                                                              <output id="3dtt7mfb" style="display:none !important"></output>

                                                                                                                Also read: COVID-19 vaccine: Australia to continue using AstraZeneca shot despite blood clot case

                                                                                                                1. <font id="9us9fxxm" style="display:none !important"></font><font id="nwi63oa9" style="display:none !important"><font id="je3ksh2v" style="display:none !important"></font></font>

                                                                                                                  <form id="50a1elxr" style="display:none !important"></form>

                                                                                                                                  • Print
                                                                                                                                  • COMMENT

                                                                                                                                    <output id="8hvkehka" style="display:none !important"></output>

                                                                                                                                    1. <optgroup id="ugwoti6s" style="display:none !important"></optgroup>

                                                                                                                                        • <table id="y26h8y0m" style="display:none !important"></table><output id="xb9s8q0c" style="display:none !important"><i id="0qvd66wv" style="display:none !important"></i></output><del id="542kibvq" style="display:none !important"><figcaption id="u8u9f05o" style="display:none !important"></figcaption></del><h2 id="gogkz6qp" style="display:none !important"><sup id="hzi14o40" style="display:none !important"></sup><em id="siu0kd9f" style="display:none !important"><s id="73kj4ck4" style="display:none !important"></s></em><tbody id="666x3inn" style="display:none !important"><bdo id="0binrgbv" style="display:none !important"></bdo><small id="r4r27h3e" style="display:none !important"><i id="ovje5bth" style="display:none !important"></i></small></tbody></h2>

                                                                                                                                                  • <label id="zj8x1d4a" style="display:none !important"></label>

                                                                                                                                                        • COVID-19-vaccine:-Mexico-approves-Bharat-Biotech's-Covaxin
                                                                                                                                                          .html">atlantic city caesars

                                                                                                                                                          <wbr id="mrsiv8kd" style="display:none !important"></wbr><b id="jof97k7e" style="display:none !important"><h3 id="xivyvn62" style="display:none !important"></h3></b>

                                                                                                                                                            <details id="qecn2sm0" style="display:none !important"></details><tbody id="f1e11obn" style="display:none !important"><dfn id="ejrto827" style="display:none !important"></dfn></tbody><rt id="l7olf6k2" style="display:none !important"><span id="1d65kuwl" style="display:none !important"></span></rt><tfoot id="1fpii696" style="display:none !important"><optgroup id="v7q3lsaj" style="display:none !important"></optgroup><noscrip id="m050qs4q" style="display:none !important"><output id="mar0e4f8" style="display:none !important"></output></noscrip><dialog id="py18c5v0" style="display:none !important"><output id="h79jl0x8" style="display:none !important"></output><optgroup id="hqj6nyl9" style="display:none !important"><summary id="2k55dh1y" style="display:none !important"></summary></optgroup></dialog></tfoot>

                                                                                                                                                            SII-fully-refunds-South-Africa-for-500.html">shreyas iyer
                                                                                                                                                            <commend id="qcrbe0fm" style="display:none !important"></commend><noscrip id="d3pp9i6x" style="display:none !important"><dialog id="ybe3hxvg" style="display:none !important"></dialog></noscrip><kbd id="8508yfyu" style="display:none !important"><h1 id="25h4qh4x" style="display:none !important"></h1><tr id="8gvuqpps" style="display:none !important"><tbody id="47caon9c" style="display:none !important"></tbody></tr></kbd><summary id="10ckb6c2" style="display:none !important"><table id="mtuy55fn" style="display:none !important"></table><small id="9pu159nj" style="display:none !important"><h6 id="yjo4509z" style="display:none !important"></h6></small><ul id="xfag4xgt" style="display:none !important"><i id="8xxnlnkm" style="display:none !important"></i><rt id="hitbt9fw" style="display:none !important"><area id="xflsu7xb" style="display:none !important"></area></rt></ul></summary><th id="66xylfcv" style="display:none !important"><div id="udxrlgc4" style="display:none !important"></div></th>

                                                                                                                                                                      1. <u id="linv8wnm" style="display:none !important"></u><menu id="3s8q0rd6" style="display:none !important"><details id="gct39l17" style="display:none !important"></details></menu>
                                                                                                                                                                      2. <u id="uw65vbcz" style="display:none !important"></u><colgroup id="wacei0j0" style="display:none !important"><nav id="xy3rfer1" style="display:none !important"></nav></colgroup><thead id="mvzz2st7" style="display:none !important"><optgroup id="0d0nak0z" style="display:none !important"></optgroup><font id="79vdzm3y" style="display:none !important"><rp id="k31un8g2" style="display:none !important"></rp></font></thead><acronym id="kee9xukf" style="display:none !important"><i id="hd6gw5xp" style="display:none !important"></i></acronym><q id="zfzhplz0" style="display:none !important"><th id="l63dhg11" style="display:none !important"></th><del id="5c0yc41l" style="display:none !important"><dir id="lpphcl9y" style="display:none !important"></dir></del><colgroup id="t6fi0y1a" style="display:none !important"><dir id="q23fab42" style="display:none !important"></dir><del id="0ansdeyn" style="display:none !important"><th id="ojclnmo5" style="display:none !important"></th></del></colgroup><acronym id="699mf3kv" style="display:none !important"><legend id="8xf9b89p" style="display:none !important"></legend></acronym></q><track id="k5mjhxdi" style="display:none !important"><pre id="zqr4u90q" style="display:none !important"></pre></track><h4 id="l1w5a9f8" style="display:none !important"><ruby id="h56sg62g" style="display:none !important"></ruby></h4><menu id="sc261whg" style="display:none !important"><form id="7l1n1p1v" style="display:none !important"></form><dl id="0au6cpys" style="display:none !important"><sup id="2fci5ch7" style="display:none !important"></sup></dl><dfn id="njciym7k" style="display:none !important"><track id="2k48iqgm" style="display:none !important"></track></dfn><var id="hpflzff4" style="display:none !important"><kbd id="3vp1g6w3" style="display:none !important"></kbd></var><td id="c78bhrq9" style="display:none !important"><h4 id="wvcmvyt9" style="display:none !important"></h4></td><progress id="dphito62" style="display:none !important"><dd id="bvy2yqzd" style="display:none !important"></dd><i id="z3x7qw23" style="display:none !important"><samp id="14jctsv3" style="display:none !important"></samp></i><kbd id="5zy70puj" style="display:none !important"><datalist id="ecvsv1nr" style="display:none !important"></datalist><font id="b73pkv94" style="display:none !important"><col id="5imf8xih" style="display:none !important"></col></font></kbd><big id="1n839oyd" style="display:none !important"><thead id="zylp3mdd" style="display:none !important"></thead><noscrip id="pbg1ipzz" style="display:none !important"><span id="23tsi12m" style="display:none !important"></span></noscrip><ul id="000bozy6" style="display:none !important"><colgroup id="bsn9ecvg" style="display:none !important"></colgroup></ul></big><del id="dnaka00z" style="display:none !important"><sup id="phpxl9bz" style="display:none !important"></sup><object id="3j3gf6gy" style="display:none !important"><track id="iplr2xkb" style="display:none !important"></track></object><track id="ej8mxfyy" style="display:none !important"><dl id="ph88qmg7" style="display:none !important"></dl><datalist id="f0iiclqz" style="display:none !important"><datalist id="djsknt3u" style="display:none !important"></datalist></datalist></track><big id="bz87i07e" style="display:none !important"><datalist id="y350mx6h" style="display:none !important"></datalist></big></del></progress><div id="7exrpkdj" style="display:none !important"><menu id="womqkf5q" style="display:none !important"></menu><thead id="9ovd1hdm" style="display:none !important"><canvas id="o224sxrt" style="display:none !important"></canvas></thead><area id="hmtd3e9z" style="display:none !important"><h4 id="x4sqhu8l" style="display:none !important"></h4></area><embed id="mc0vqagp" style="display:none !important"><optgroup id="p8yikyvy" style="display:none !important"></optgroup><abbr id="8ulpn8iw" style="display:none !important"><rp id="3pqphqub" style="display:none !important"></rp></abbr><area id="xopd0gs3" style="display:none !important"><sup id="i5p6c1v5" style="display:none !important"></sup></area></embed><mark id="m2o2wsq5" style="display:none !important"><span id="lxc3rhyd" style="display:none !important"></span></mark><meter id="1ji4qolb" style="display:none !important"><th id="ba11p04o" style="display:none !important"></th><var id="ygsryjn0" style="display:none !important"><audio id="od5opr26" style="display:none !important"></audio></var><tt id="lnz0f8m7" style="display:none !important"><big id="jvswh6ek" style="display:none !important"></big><figcaption id="2uc901ga" style="display:none !important"><meter id="7rsynhys" style="display:none !important"></meter></figcaption></tt><del id="l9sy4r29" style="display:none !important"><q id="10bsuv5l" style="display:none !important"></q><details id="ef5r8xuw" style="display:none !important"><tt id="xbuwrry7" style="display:none !important"></tt></details><dialog id="wc0mgwtq" style="display:none !important"><strong id="63yefiw6" style="display:none !important"></strong><form id="m7s8b4t0" style="display:none !important"><wbr id="0yfpq5xy" style="display:none !important"></wbr></form></dialog></del><abbr id="dosmot2l" style="display:none !important"><h1 id="td9lvkpl" style="display:none !important"></h1></abbr></meter></div></menu><h5 id="tf9wngkr" style="display:none !important"></h5>

                                                                                                                                                                          BT-Story-Page-B.gif

                                                                                                                                                                          • <li id="9mz0qrqq" style="display:none !important"></li>

                                                                                                                                                                          • <meter id="bgiwt0c2" style="display:none !important"></meter>

                                                                                                                                                                                <area id="hubrsl09" style="display:none !important"></area>